Synbiotics, a subsidiary of Ambalal Sarabhai Enterprises, is the only manufacturer of the Active Pharmaceutical Ingredient (API) Amphotericin B in India and looking at the current outbreak of the disease and expected requirement, Synbiotics has ramped up the manufacturing capacity to meet the requirement of the same, the company said in BSE filing on Tuesday, May 11, 2021.
Earlier, on May 3, the company had informed that CoSara Diagnostics Private Limited (“CoSara”), a joint venture of a subsidiary of Ambalal Sarabhai Enterprises Limited and Co-Diagnostics, Inc, Salt Lake City, Utah, USA has been featured in the recent press, highlighting its actions to provide much-needed Covid-19 diagnostics as a wave of infections has led to the world's worst outbreak since the pandemic began.
CoSara's partners and distributors have also assisted in setting up nearly a dozen Molecular labs from the ground up. It forms an integral part of our mission to bring high-quality, affordable molecular diagnostics solutions to the world, the company said.
Ambalal Sarabhai Enterprises produces a range of bulk drugs pharmaceutical preparations and electronic instruments. The company operates in two segments, namely pharmaceuticals and electronics. The pharmaceuticals segment is engaged in the manufacturing of drugs and formulations while the electronics segment is engaged in the production of electronic instruments and services.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.